临床纳米和微粒制剂用于治疗药物传递的历史透视。
Historical Perspective of Clinical Nano and Microparticle Formulations for Delivery of Therapeutics.
机构信息
Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina, Chapel Hill, NC 27599, USA.
Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North State University, Chapel Hill, NC 27599, USA.
出版信息
Trends Mol Med. 2021 Jun;27(6):516-519. doi: 10.1016/j.molmed.2021.04.002. Epub 2021 Apr 23.
Abstract
Nano and micro-technologies are used for therapeutic delivery of biologics and small molecules in formulations ranging in size from one nanometer to 100 microns or more. Here we review the unique physiochemical properties of these technologies and how they lead to more beneficial drug pharmacokinetics and toxicity over conventional formulations.
摘要
纳米和微技术用于生物制剂和小分子的治疗性递药，制剂的大小范围从一纳米到 100 微米或更大。在这里，我们回顾了这些技术的独特物理化学性质，以及它们如何导致比传统制剂更有益的药物药代动力学和毒性。
相似文献
1
Historical Perspective of Clinical Nano and Microparticle Formulations for Delivery of Therapeutics.临床纳米和微粒制剂用于治疗药物传递的历史透视。
Trends Mol Med. 2021 Jun;27(6):516-519. doi: 10.1016/j.molmed.2021.04.002. Epub 2021 Apr 23.
2
Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems.纳米颗粒和纳米给药系统的药物研发和监管考虑因素。
J Pharm Sci. 2013 Nov;102(11):3867-82. doi: 10.1002/jps.23691. Epub 2013 Aug 23.
3
Nano-formulations of drugs: Recent developments, impact and challenges.药物的纳米制剂：最新进展、影响及挑战
Biochimie. 2016 Sep-Oct;128-129:99-112. doi: 10.1016/j.biochi.2016.07.008. Epub 2016 Jul 18.
4
Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective.聚合物颗粒技术用于口服药物传递和靶向给药：病理生理学视角。
Nanomedicine. 2012 Sep;8 Suppl 1:S5-20. doi: 10.1016/j.nano.2012.07.005. Epub 2012 Jul 27.
5
Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.使用聚（D，L-丙交酯-共-乙交酯）及其衍生物递送大分子治疗药物的纳米/微技术
J Control Release. 2008 Feb 11;125(3):193-209. doi: 10.1016/j.jconrel.2007.09.013. Epub 2007 Oct 22.
6
Recent Developments in the Application of Polymeric Nanoparticles as Drug Carriers.聚合物纳米颗粒作为药物载体应用的最新进展
Adv Clin Exp Med. 2015 Sep-Oct;24(5):749-58. doi: 10.17219/acem/31802.
7
Recent Trends in Clinical Trials Related to Carrier-Based Drugs.基于载体的药物相关临床试验的近期趋势。
J Pharm Sci. 2017 Sep;106(9):2219-2226. doi: 10.1016/j.xphs.2017.02.026. Epub 2017 Mar 1.
8
Double emulsions prepared by two-step emulsification: History, state-of-the-art and perspective.两步乳化法制备的双乳液：历史、现状和展望。
J Control Release. 2019 Feb 10;295:31-49. doi: 10.1016/j.jconrel.2018.12.037. Epub 2018 Dec 21.
9
Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles.利用聚合物纳米粒的物理和化学策略进行治疗性递药。
Pharmacol Rev. 2012 Jul;64(3):505-19. doi: 10.1124/pr.111.005363. Epub 2012 Apr 27.
10
Nanocarriers for oral drug delivery.纳米载体用于口服药物递送。
J Drug Target. 2013 Jul;21(6):515-27. doi: 10.3109/1061186X.2013.789033. Epub 2013 Apr 26.
引用本文的文献
1
Nanoparticles for Cancer Immunotherapy: Innovations and Challenges.用于癌症免疫治疗的纳米颗粒：创新与挑战
Pharmaceuticals (Basel). 2025 Jul 22;18(8):1086. doi: 10.3390/ph18081086.
2
Application of Biomimetic Cell Membrane-Coated Nanocarriers in Cardiovascular Diseases.仿生细胞膜包覆纳米载体在心血管疾病中的应用
Int J Nanomedicine. 2025 Jun 26;20:8249-8289. doi: 10.2147/IJN.S531558. eCollection 2025.
3
Potential Applications of Natural Components of Traditional Chinese Medicine Delivery via Nanoparticle Drug Delivery Systems in the Treatment of Alzheimer's Disease.基于纳米颗粒给药系统的中药天然成分在阿尔茨海默病治疗中的潜在应用
Int J Nanomedicine. 2025 Jun 17;20:7781-7810. doi: 10.2147/IJN.S525960. eCollection 2025.
4
Advancing fungal keratitis treatment: transitioning from conventional amphotericin B therapy to nanocarrier-based delivery systems.推进真菌性角膜炎治疗：从传统两性霉素B疗法向基于纳米载体的递送系统转变。
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 17. doi: 10.1007/s00210-025-04268-8.
5
Engineered nanoparticles as a promising drug delivery system for glioblastoma multiforme treatment.工程纳米颗粒作为一种用于多形性胶质母细胞瘤治疗的有前景的药物递送系统。
Ther Deliv. 2025 Jun;16(6):593-606. doi: 10.1080/20415990.2025.2484170. Epub 2025 Mar 25.
6
Nanomedicine: The new trend and future of precision medicine for inflammatory bowel disease.纳米医学：炎症性肠病精准医学的新趋势与未来
Chin Med J (Engl). 2024 Dec 20;137(24):3073-3082. doi: 10.1097/CM9.0000000000003413. Epub 2024 Dec 16.
7
The potential of nano- and microparticle-based influenza vaccines with enhanced shelf lives.具有延长保质期的基于纳米和微粒的流感疫苗的潜力。
Nanomedicine (Lond). 2024;19(26):2135-2138. doi: 10.1080/17435889.2024.2392484. Epub 2024 Oct 8.
8
Current research trends of nanomedicines.纳米药物的当前研究趋势。
Acta Pharm Sin B. 2023 Nov;13(11):4391-4416. doi: 10.1016/j.apsb.2023.05.018. Epub 2023 May 20.
9
The Use of Particulate Systems for Tuberculosis Prophylaxis and Treatment: Opportunities and Challenges.颗粒系统在结核病预防和治疗中的应用：机遇与挑战
Microorganisms. 2023 Aug 2;11(8):1988. doi: 10.3390/microorganisms11081988.
10
An Overview of the Use of Nanoparticles in Vaccine Development.纳米颗粒在疫苗研发中的应用概述
Nanomaterials (Basel). 2023 Jun 9;13(12):1828. doi: 10.3390/nano13121828.
本文引用的文献
1
Nanotechnology for modern medicine: next step towards clinical translation.纳米技术在现代医学中的应用：迈向临床转化的下一步。
J Intern Med. 2021 Sep;290(3):486-498. doi: 10.1111/joim.13254. Epub 2021 Mar 31.
2
ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper.ARIA-EAACI 关于 COVID-19 疫苗严重过敏反应的声明——一份 EAACI-ARIA 立场文件。
Allergy. 2021 Jun;76(6):1624-1628. doi: 10.1111/all.14726.
3
Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing.用于组织特异性 mRNA 递药和 CRISPR-Cas 基因编辑的选择性器官靶向（SORT）纳米颗粒。
Nat Nanotechnol. 2020 Apr;15(4):313-320. doi: 10.1038/s41565-020-0669-6. Epub 2020 Apr 6.
4
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs.Onpattro的故事以及含核酸类药物的纳米药物的临床转化。
Nat Nanotechnol. 2019 Dec;14(12):1084-1087. doi: 10.1038/s41565-019-0591-y.
5
Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.编码 HIV 包膜免疫原的 RNA 复制子的免疫原性，这些免疫原设计用于自组装成纳米颗粒。
Mol Ther. 2019 Dec 4;27(12):2080-2090. doi: 10.1016/j.ymthe.2019.08.007. Epub 2019 Aug 19.
6
Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties.脂质纳米颗粒的血液清除加速需要B-1淋巴细胞随后是B-2淋巴细胞对不同抗原部分的双相体液反应。
Immunohorizons. 2019 Jul 11;3(7):282-293. doi: 10.4049/immunohorizons.1900029.
7
The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes.聚合物主链化学对聚合物修饰脂质体中加速血液清除诱导的影响。
J Control Release. 2015 Sep 10;213:1-9. doi: 10.1016/j.jconrel.2015.06.023. Epub 2015 Jun 18.
8
Formulation and pharmacology of long-acting rilpivirine.长效利匹韦林的制剂与药理学
Curr Opin HIV AIDS. 2015 Jul;10(4):233-8. doi: 10.1097/COH.0000000000000164.
9
Zwitteration: coating surfaces with zwitterionic functionality to reduce nonspecific adsorption.两性离子化：用具有两性离子功能的物质包覆表面以减少非特异性吸附。
Langmuir. 2014 Aug 19;30(32):9625-36. doi: 10.1021/la500057j. Epub 2014 Apr 22.
10
An overview of clinical and commercial impact of drug delivery systems.药物递送系统的临床和商业影响概述。
J Control Release. 2014 Sep 28;190:15-28. doi: 10.1016/j.jconrel.2014.03.053. Epub 2014 Apr 18.
Zotero 插件